Gene transcription profiles in fibrocystic breast disease

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective: To investigate gene transcription profiles and identify differences in gene expression between different forms of fibrocystic breast disease (FBD).

Materials and methods: We studied 128 formalin-fixed, paraffin-embedded breast tissue samples obtained at the time of surgery with histologically confirmed non-proliferative FBD, typical ductal hyperplasia, atypical ductal hyperplasia, ductal carcinoma in situ, and normal tissue. The expression profiles of the 46 candidate genes were analyzed by real-time quantitative PCR.

Results: Depending on the histological type of the sample, we established the general patterns of mRNA expression of the genes studied in different forms of FBD, and the spectra of differentially expressed genes in proliferative FBD with atypia (18 genes) and non-proliferative forms of FBD (14 genes).

Conclusion: Proliferative FBD with atypia, which carries the highest risk of developing breast cancer, is characterized by a statistically significant increase in the mRNA expression of MKI67, CCNB1, KIF14, PTTG1, ANLN, TMEM45B, TPX2, PRLR, FGFR4, MMP11, GATA3, EXO1, TYMS, and NAT1, and a decrease in the mRNA expression of MYC, RANK, TNFA, and MMP9.

全文:

受限制的访问

作者简介

Olga Burmenskaya

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: o_bourmenskaya@oparina4.ru
ORCID iD: 0000-0003-2842-3980

Dr. Bio. Sci., Head of the Laboratory of Oncological Genetics

俄罗斯联邦, 117997, Moscow, Ac. Oparina str., 4

Vlada Kometova

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: v_kometova@oparina4.ru
ORCID iD: 0000-0001-9666-6875

PhD, Head of Oncopathology Department

俄罗斯联邦, 117997, Moscow, Ac. Oparina str., 4

Antonina Smetnik

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: a_smetnik@oparina4.ru
ORCID iD: 0000-0002-0627-3902

PhD, Head of the Department of Gynecological Endocrinology

俄罗斯联邦, 117997, Moscow, Ac. Oparina str., 4

Valery Rodionov

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: v_rodionov@oparina4.ru
ORCID iD: 0000-0003-0096-7126

Professor, Dr. Med. Sci., Head of Breast Cancer Department

俄罗斯联邦, 117997, Moscow, Ac. Oparina str., 4

Dmitry Trofimov

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: d_trofimov@oparina4.ru
ORCID iD: 0000-0002-1569-8486

Corresponding Member of the RAS, Professor, Dr. Med. Sci., Director of the Institute of Reproductive Genetics

俄罗斯联邦, 117997, Moscow, Ac. Oparina str., 4

Lev Ashrafyan

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: levaa2004@yahoo.com
ORCID iD: 0000-0001-6396-4948

Dr. Med. Sci., Professor, Academician of RAS, Head of the Institute of Oncogynecology and Mammology, Deputy Director

俄罗斯联邦, 117997, Moscow, Ac. Oparina str., 4

Gennady Sukhikh

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation

Email: g_sukhikh@oparina4.ru
ORCID iD: 0000-0002-7712-1260

Academician of RAS, Professor, Dr. Med. Sci., Director

俄罗斯联邦, 117997, Moscow, Ac. Oparina str., 4

参考

  1. Каприн А.Д., Рожкова Н.И., ред. Маммология. Национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2016. 496с. [Kaprin A.D., Rozhkova N.I., eds. Mammology. National guide. 2nd ed. Moscow: GEOTAR-Media; 2016. 496p. (in Russian)].
  2. Dyrstad S., Yan Y., Fowler A., Colditz G.A. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res. Treat. 2015; 149(3): 569-75. https://dx.doi.org/10.1007/s10549-014-3254-6.
  3. Onstad M., Stuckey A. Benign breast disorders. Obstet. Gynecol. Clin. North Am. 2013; 40(3): 459-73. https://dx.doi.org/10.1016/j.ogc.2013.05.004.
  4. Рожкова Н.И., Меских Е.В., Бурдина Л.М., Сметник В.П., Бурдина И.И. Лекарственная патогенетическая коррекция доброкачественных заболеваний молочной железы. Опухоли женской репродуктивной системы. 2008; 2: 48-54. [Rozhkova N.I., Meskikh Y.V., Burdina L.M., Smetnik V.P., Burdina I.I. Medical pathogenetic correction of benign breast disorders. Tumors of Female Reproductive System. 2008; (2): 48-54. (in Russian)]. https://dx.doi.org/10.17650/1994-4098-2008-0-2-48-54.
  5. Román M., Louro J., Posso M., Alcántara R., Peñalva L., Sala M. et al. Breast density, benign breast disease, and risk of breast cancer over time. Eur. Radiol. 2021; 31(7): 4839-47. https://dx.doi.org/10.1007/ s00330-020-07490-5.
  6. Керчелаева С.Б., Сметник А.А., Беспалов В.Г. Мастопатия и профилактика рака молочной железы как междисциплинарная проблема. РМЖ. Мать и дитя. 2016; 24(15): 1018-25. [Kerchelaeva S.B., Smetnik A.A., Bespalov V.G. Mastopathy and breast cancer prevention as interdisciplinary problem. RMJ. 2016; 24(15): 1018-25. (in Russian)].
  7. Hartmann L.C., Sellers T.A., Frost M.H., Lingle W.L., Degnim A.C., Ghosh K. et al. Benign breast disease and the risk of breast cancer. N. Engl. J. Med. 2005; 353(3): 229-37. https://dx.doi.org/10.1056/ NEJMoa044383.
  8. Бурменская О.В., Трофимов Д.Ю., Кометова В.В., Сергеев И.В., Маерле А.В., Родионов В.В., Сухих Г.Т. Разработка и опыт использования транскрипционной сигнатуры генов в диагностике молекулярных подтипов рака молочной железы. Акушерство и гинекология. 2020; 2: 132-40. [Burmenskaya O.V., Trofimov D.Yu., Kometova V.V., Sergeev I.V., Maerle A.V., Rodionov V.V., Sukhikh G.T. Development and experience of using the transcriptional gene signature in the diagnosis of molecular breast cancer subtypes. Obstetrics and Gynecology. 2020; (2): 132-40. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.2.132-140.
  9. Schmittgen T.D., Zakrajsek B.A., Mills A.G., Gorn V., Singer M.J., Reed M.W. Quantitative reverse transcription–polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal. Biochem. 2000; 285(2): 194-204. https://dx.doi.org/10.1006/abio.2000.4753.
  10. Chiang H.C., Zhang X., Li J., Zhao X., Chen J., Wang H.T. et al. BRCA1-associated R-loop affects transcription and differentiation in breast luminal epithelial cells. Nucleic Acids Res. 2019; 47(10): 5086-99. https://dx.doi.org/10.1093/nar/gkz262.
  11. Родионова M.В., Воротников И.К., Родионов В.В., Чхиквадзе Н.В., Дудко Е.А., Рябчиков Д.А., Ошкина Е.В., Богуш Т.А. Эстрогеновые рецепторы бета как маркеры эффективности гормональной терапии рака молочной железы. Российский биотерапевтический журнал. 2015; 14(2): 39-40. [Rodionova M.V., Vorotnikov I.K., Rodionov V.V., Chkhivladze N.V., Dudko E.A., Ryabchikov D.A., Oshkina E.V., Bogush T.A. Role of estrogen beta in the development and treatment of breast cancer. Russian Biotherapeutic Journal. 2015; 14(2): 39-40. (in Russian)].
  12. Sotoca A.M., van den Berg H., Vervoort J., van der Saag P., Ström A., Gustafsson J.-A. et al. Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci. 2008; 105(2): 303-11. https://dx.doi.org/10.1093/ toxsci/kfn141.
  13. Chaudhary S., Krishna B.M., Mishra S.K. A novel FOXA1/ ESR1 interacting pathway: A study of ncomine breast cancer omicroarrays. Oncol. Lett. 2017; 14(2): 1247-64. https://dx.doi.org/10.3892/ ol.2017.6329.
  14. Sircoulomb F., Nicolas N., Ferrari A., Finetti P., Bekhouche I., Rousselet E. et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol. Med. 2011; 3(3): 153-66. https://dx.doi.org/10.1002/ emmm.201100121.
  15. Zhang X., Mu X., Huang O., Wang Z., Chen J., Chen D., Wang G. ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis. BMC Cancer. 2022; 22(1): 226. https://dx.doi.org/10.1186/s12885-022-09286-w.
  16. Clevenger C.V., Rui H. Breast cancer and prolactin - new mechanisms and models. Endocrinology. 2022; 163(10): bqac122. https://dx.doi.org/10.1210/endocr/bqac122.
  17. Kim G., Lee J.G., Cheong S.A., Yon J.M., Lee M.S., Hong E.J., Baek I.J. Progesterone receptor membrane component 1 is required for mammary gland development. Biol. Reprod. 2020; 103(6): 1249-59. https://dx.doi.org/10.1093/biolre/ioaa164.
  18. Li X., Ruan X., Gu M., Mueck A.O. PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol. Climacteric. 2019; 22(5): 483-8. https://dx.doi.org/10.1080/ 13697137.2019.1582624.
  19. Cahill М.А., Neubauer H. PGRMC proteins are coming of age: a special issue on the role of PGRMC1 and PGRMC2 in metabolism and cancer biology. Cancers (Basel). 2021; 13(3): 512. https://dx.doi.org/10.3390/cancers13030512.
  20. Helsten T., Elkin S., Arthur E., Tomson B.N., Carter J., Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 2016; 22(1): 259-67. https://dx.doi.org/10.1158/ 1078-0432.CCR-14-3212.
  21. Infante M., Fabi A., Cognetti F., Gorini S., Caprio M., Fabbri A. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J. Exp. Clin. Cancer Res. 2019; 38(1): 12. https://dx.doi.org/10.1186/s13046-018-1001-2.
  22. Tiang J.M., Butcher N.J., Minchin R.F. Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines. Cancer Med. 2015; 4(4): 565-74. https://dx.doi.org/10.1002/cam4.415.
  23. Li P., Butcher N.J., Minchin R.F. Arylamine N-acetyltransferase i regulates expression of matrix metalloproteinase 9 in breast cancer cells: role of hypoxia-inducible factor 1-α. Mol. Pharmacol. 2019; 96(5): 573-9. https://dx.doi.org/10.1124/mol.119.117432.
  24. Merdad A., Karim S., Schulten H.J., Dallol A., Buhmeida A., Al-Thubaity F. et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res. 2014; 34(3): 1355-66.
  25. Vandooren J., Van den Steen P.E., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit. Rev. Biochem. Mol. Biol. 2013; 48(3): 222-72. https://dx.doi.org/10.3109/10409238.2013.770819.
  26. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D. et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998; 93(3): 411-22. https://dx.doi.org/10.1016/s0092-8674(00)81169-1.
  27. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B. et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002; 8(8): 793-800. https://dx.doi.org/10.1038/nm730.
  28. Боголюбова А.В., Ефимов Г.А., Друцкая М.С., Недоспасов С.А. Иммунотерапия опухолей, основанная на блокировке иммунологических контрольных «точек» («чекпойнтов»). Медицинская иммунология. 2015;17(5): 395-406. [Bogolyubova A.V., Efimov G.A., Drutskaya M.S., Nedospasov S.A. Cancer immunotherapy based on the blockade of immune checkpoints. Medical Immunology (Russia). 2015; 17(5): 395-406. (in Russian)].

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1

下载 (208KB)
索引源数据
3. Fig. 2

下载 (323KB)
索引源数据
4. Fig. 3

下载 (132KB)
索引源数据

版权所有 © Bionika Media, 2023
##common.cookie##